MediciNova (MNOV) Q2 2024 earnings summary

Executive summary

• Focused on developing novel therapeutics for serious diseases with unmet medical needs, primarily in the U.S. market.

• Pipeline includes MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, with additional candidates for asthma and cancer.

• Strategy emphasizes advancing lead programs through investigator-sponsored and grant-funded trials, and seeking strategic partnerships.

• Accumulated deficit reached $421.1 million as of June 30, 2024, with expectations of continued net losses as development progresses.

Financial highlights

• Cash and cash equivalents were $44.3 million as of June 30, 2024, down from $51.0 million at year-end 2023.

• Working capital stood at $43.0 million as of June 30, 2024.

• Net loss for Q2 2024 was $5.4 million, compared to $5.8 million in Q2 2023; net loss for the six months ended June 30, 2024 was $8.0 million, compared to $8.7 million in the prior year period.

• Operating expenses for Q2 2024 were $3.0 million, down from $3.3 million in Q2 2023.

• Interest income decreased to $0.4 million in Q2 2024 from $0.5 million in Q2 2023.

Outlook and guidance

• Management believes current working capital is sufficient to fund operations at least through the end of 2025.

• Continued focus on advancing clinical programs and seeking non-dilutive funding and strategic alliances.